Status:
COMPLETED
Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD
Lead Sponsor:
Maisonneuve-Rosemont Hospital
Collaborating Sponsors:
Fonds de recherche en ophtalmologie de l'Université de Montréal
Foundation Fighting Blindness
Conditions:
Exudative Age Related Macular Degeneration
Eligibility:
All Genders
50-100 years
Phase:
NA
Brief Summary
The purpose of this trial is to detect the influence of omega-3 supplements on vitreous levels of vascular endothelial growth factor (VEGF) in exudative age-related macular degeneration (AMD) in patie...
Detailed Description
The purpose of this trial is to detect the influence of omega-3 supplements on vitreous levels of vascular endothelial growth factor (VEGF) in exudative age-related macular degeneration (AMD) in patie...
Eligibility Criteria
Inclusion
- wet AMD eligible for intravitreal anti-VEGF treatment.
- Confirmed exudation on SD-OCT.
Exclusion
- dry AMD.
- Disciform scar.
- Smokers.
- Morbid obesity.
- Patients undergoing other forms of treatment for wet AMD.
Key Trial Info
Start Date :
February 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01819415
Start Date
February 1 2011
End Date
February 1 2013
Last Update
April 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maisonneuve Rosemont Hospital
Montreal, Quebec, Canada, H1T2M4